Tolvaptan in Later-Stage Polycystic Kidney Disease.
作者信息
Torres Vicente E, Gansevoort Ron T, Czerwiec Frank S
机构信息
Mayo Clinic, Rochester, MN
University Medical Center Groningen, Groningen, the Netherlands
出版信息
N Engl J Med. 2018 Feb 1;378(5):489-490. doi: 10.1056/NEJMc1716478.
Abstract
摘要
相似文献
1
Tolvaptan in Later-Stage Polycystic Kidney Disease.托伐普坦用于晚期多囊肾病
N Engl J Med. 2018 Feb 1;378(5):489-490. doi: 10.1056/NEJMc1716478.
2
Tolvaptan in Later-Stage Polycystic Kidney Disease.托伐普坦用于晚期多囊肾病
N Engl J Med. 2018 Feb 1;378(5):488-9. doi: 10.1056/NEJMc1716478.
3
Tolvaptan in Later-Stage Polycystic Kidney Disease.托伐普坦用于晚期多囊肾病
N Engl J Med. 2018 Feb 1;378(5):488. doi: 10.1056/NEJMc1716478.
4
Clinical experience with tolvaptan in patients with polycystic kidney disease.托伐普坦治疗多囊肾病患者的临床经验。
Med Clin (Barc). 2020 Jul 24;155(2):83-84. doi: 10.1016/j.medcli.2019.03.011. Epub 2019 May 23.
5
The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease.托伐普坦对常染色体显性遗传性多囊肾病患者肾功能的影响。
Clin Exp Nephrol. 2016 Feb;20(1):147-8. doi: 10.1007/s10157-015-1134-y. Epub 2015 Jun 13.
6
Tolvaptan and Autosomal Dominant Polycystic Kidney Disease.托伐普坦与常染色体显性多囊肾病
N Engl J Med. 2017 Nov 16;377(20):1988-1989. doi: 10.1056/NEJMe1714276. Epub 2017 Nov 4.
7
Doubts about the efficacy of tolvaptan for polycystic kidney disease.对托伐普坦治疗多囊肾病疗效的质疑。
Clin Nephrol. 2020 Jun;93(6):307-309. doi: 10.5414/CN109927Letter.
8
REPRISE: tolvaptan in advanced polycystic kidney disease.再论：托伐普坦用于晚期多囊肾病
Kidney Int. 2018 Feb;93(2):292-295. doi: 10.1016/j.kint.2017.12.002.
9
Tolvaptan in autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传性多囊肾病
N Engl J Med. 2013 Mar 28;368(13):1259. doi: 10.1056/NEJMc1300762.
10
Tolvaptan in autosomal dominant polycystic kidney disease.托伐普坦用于常染色体显性多囊肾病的治疗
N Engl J Med. 2013 Mar 28;368(13):1258-9. doi: 10.1056/NEJMc1300762.
引用本文的文献
1
A novel rapalog shows improved safety vs. efficacy in a human organoid model of polycystic kidney disease.一种新型雷帕霉素类似物在多囊肾病的人体类器官模型中显示出更好的安全性与有效性。
Stem Cell Reports. 2025 Feb 11;20(2):102395. doi: 10.1016/j.stemcr.2024.102395. Epub 2025 Jan 23.
2
Long-term effect of increasing water intake on repeated self-assessed health-related quality of life (HRQoL) in autosomal dominant polycystic kidney disease.增加饮水量对常染色体显性多囊肾病患者反复自我评估的健康相关生活质量（HRQoL）的长期影响。
Clin Kidney J. 2024 Jun 7;17(7):sfae159. doi: 10.1093/ckj/sfae159. eCollection 2024 Jul.
3
An Artificial Intelligence Generated Automated Algorithm to Measure Total Kidney Volume in ADPKD.一种用于测量常染色体显性多囊肾病中总肾体积的人工智能生成的自动化算法。
Kidney Int Rep. 2023 Nov 4;9(2):249-256. doi: 10.1016/j.ekir.2023.10.029. eCollection 2024 Feb.
4
Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease.在多囊肾病的人体芯片类器官模型中，葡萄糖吸收驱动囊肿形成。
Nat Commun. 2022 Dec 23;13(1):7918. doi: 10.1038/s41467-022-35537-2.
5
Drug management of autosomal dominant polycystic kidney disease.常染色体显性多囊肾病的药物治疗
Aust Prescr. 2022 Oct;45(5):167-170. doi: 10.18773/austprescr.2022.052. Epub 2022 Oct 4.
6
Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling.聚焦于环磷酸腺苷信号传导的常染色体显性多囊肾病新兴疗法
Front Mol Biosci. 2022 Sep 2;9:981963. doi: 10.3389/fmolb.2022.981963. eCollection 2022.
7
Effects of Suramin on Polycystic Kidney Disease in a Mouse Model of Polycystin-1 Deficiency.苏拉明对多囊蛋白-1 缺陷型小鼠多囊肾病的作用。
Int J Mol Sci. 2022 Jul 31;23(15):8499. doi: 10.3390/ijms23158499.
8
Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era?近期临床试验对肾脏病学实践的影响：我们正处于停滞时代吗？
Kidney Dis (Basel). 2019 Mar;5(2):69-80. doi: 10.1159/000495139. Epub 2018 Dec 19.
9
Increased salt intake does not worsen the progression of renal cystic disease in high water-loaded PCK rats.高水负荷 PCK 大鼠中，增加盐摄入量不会加重肾囊性疾病的进展。
PLoS One. 2019 Mar 14;14(3):e0207461. doi: 10.1371/journal.pone.0207461. eCollection 2019.
本文引用的文献
1
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.托伐普坦治疗晚期常染色体显性遗传性多囊肾病。
N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.
2
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.托伐普坦对不同肾功能水平常染色体显性多囊肾病个体的短期疗效。
Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.
3
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.托伐普坦对常染色体显性多囊肾病患者肾功能和容量的短期影响。
Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4.
4
Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells.血管加压素通过致密斑细胞中的V1a受体调节肾素-血管紧张素-醛固酮系统。
Am J Physiol Renal Physiol. 2008 Jul;295(1):F100-7. doi: 10.1152/ajprenal.00088.2008. Epub 2008 Apr 30.
5
Vasopressin stimulates Cl- transport in ascending thin limb of Henle's loop in hamster.血管加压素刺激仓鼠髓袢升支细段的氯离子转运。
J Clin Invest. 1995 Apr;95(4):1623-7. doi: 10.1172/JCI117836.
Zotero 插件